This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 11
  • /
  • EU approves Abilify Maintena for Schizophrenia- Lu...
Drug news

EU approves Abilify Maintena for Schizophrenia- Lundbeck/Otsuka

Read time: 1 mins
Last updated:22nd Nov 2013
Published:22nd Nov 2013
Source: Pharmawand

Lundbeck and Otsuka announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of Schizophrenia in adult patients stabilised with oral aripiprazole. Abilify Maintena reduces the risk of relapse relative to placebo over the long-term and provides effective treatment of Schizophrenia. It has a tolerability profile similar to oral aripiprazole, and demonstrated statistically significant benefits on patients' personal and social functioning as compared to placebo.

93% of patients treated with Abilify Maintena were extremely, very or somewhat satisfied with their treatment at the end of the double-blind treatment phase.


Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.